The fund provides exposure to biotech companies involved in the use of biological processes to develop products or provide services. The underlying index contains 30 names, an increase from 20 in October 2014. Without a specific sector classification scheme, the funds broad exposure could include access to pharmaceuticals and medical technology in addition to traditional biotech. Still, FBTs equal weighting of about 30 stocks produces a relatively concentrated basket. The index is reconstituted and rebalanced quarterly.